Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Annals of Translational Medicine|April 18, 2022
Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case reportKeyi Jia, Shuo Yang, Bin Chen, et al.
Acta Pharmaceutica Sinica. B|November 3, 2021
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapyMinlin Jiang, Keyi Jia, Lei Wang, et al.
Aging|February 16, 2021
Early diagnosis of lung cancer: which is the optimal choice?Jing Ning, Tao Ge, Minlin Jiang, et al.
Translational Lung Cancer Research|February 4, 2020
T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancerKeyi Jia, Yayi He, Rafal Dziadziuszko, et al.
Annals of Translational Medicine|August 15, 2020
Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunctionJuan Deng, Xiaoxia Chen, Hui Sun, et al.
Oncotargets and Therapy|August 6, 2020
Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung CancerChenglong Sun, Liping Zhang, Wei Zhang, et al.
Translational Lung Cancer Research|April 23, 2021
High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterationsYiwei Liu, Wanying Wang, Fengying Wu, et al.
Genomics|March 11, 2021
Aberrant methylation modifications reflect specific drug responses in small cell lung cancerPeixin Chen, Haoyue Guo, Yu Liu, et al.
Translational Lung Cancer Research|March 10, 2023
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutationsHaowei Wang, Lei Cheng, Chao Zhao, et al.
Frontiers in Oncology|March 29, 2021
Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLCSangtian Liu, Fengying Wu, Xuefei Li, et al.
Pageof 3